Interim report
Page 1
1 Half-Year Report, H1 2026 20 August 2026
Page 2
2 Forward-looking statements Certain information set forth and given in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of ViroGates A/S (ViroGates); (ii) the expected development of ViroGates’ business, projects and joint ventures; (iii) execution of ViroGates’ vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for ViroGates’ projects; (v) completion of ViroGates’ projects that are currently underway, in development or otherwise under consideration; (vi) renewal of ViroGates’ current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of ViroGates believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. ViroGates undertakes no obligation to update forward- looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Page 3
3 Contents Summary Management review Financial statements Statement by the Board and Executive Management 4 9 14 23 On 20 August 2026, the Board of Directors approved the interim report for the first half of 2026 (the period 1 January – 30 June 2026) for ViroGates A/S. The interim report is unaudited.
Page 4
4 Contents Summary Management review Financial statements Statement by the Board and Executive Management 4 9 14 23
Page 5
5 Letter from the CEO We are happy to report that revenue for the first half of 2026 rose markedly compared with the same period last year. However, the increase largely reflects our U.S. partner taking delivery of the minimum order under our distribution agreement, and not yet a broad-based rollout in the U.S. market. We remain closely engaged with suPARbio to support where we can and enter the second half of the year with enthusiasm for our strategy, partnerships, and revamped commercial organization. The first half of 2026 saw a notable year-on-year increase in revenue, which is greatly encouraging. At the same time, we want to be transparent about its underlying dynamics. A large part of the increase is attributable to deliveries to our U.S. commercial partner, suPARbio , in accordance with the minimum binding order set forth in our 2024 distribution agreement. We remain very enthusiastic about this collaboration and the opportunity it represents for suPARnostic® in the U.S. longevity and preventive health market. We remain in close, ongoing contact with suPARbio and continue to support them operationally – from technical and product guidance to the practical work involved in getting suPARnostic® set up and running in laboratories – as they build out testing capacity. What remains pending is the introduction of suPARnostic® into higher-volume commercial sales channels to enable testing at scale. We look forward to reporting on that progress as it materializes. Together with our continued partner Swedish Orphan Biovitrum (Sobi), we submitted our De Novo application to the U.S. FDA for suPARnostic® TurbiLatex. This was an important milestone on the path to U.S. regulatory clearance and a prerequisite for broader commercialization of this product line in the U.S. market. We expect the FDA to request additional data as part of its review, and generating and submitting that data will represent a significant ongoing commitment for ViroGates. Our suPARnostic® POC+ device, developed in collaboration with GENSPEED Biotech and designed for decentralized, near-patient longevity testing, has moved from proof of concept to further testing and validation. This is an encouraging step; further testing is required before we can confirm performance under standard operating conditions and move toward market registration under the IVDR (market authorization in the EU). We will update the market as this work progresses. After the reporting period, on 3 August 2026, we announced changes to our commercial organization, moving from a traditional, sales-led model toward a business-development model built around larger, more scalable partnerships with clinics, laboratories, and commercial partners. Alexandre ("Alex") Delatour has joined as our newly appointed VP of Business Development, reporting to the CEO, while Thomas Krarup, VP of Sales & Marketing, has decided to leave ViroGates at the end of September. We remain very optimistic about this transition but also recognize that organizational change does not translate immediately into a comparable step-up in commercial output. Our expectations for the second half of 2026 are adjusted to account for this. ViroGates will also focus on the transition to the IVDR regulatory scheme in the EU and dedicate resources to the next steps in upgrading ISO systems and technical documentation to prepare for an audit by the Notified Body. As a result of the above developments, we recently adjusted our financial guidance, stating expected revenue of DKK 6.5-8 million, with EBIT maintained at DKK -10 to -12 million (cf. Company Announcement No. 7-2026). We enter the second half of 2026 with a U.S. partnership operationally geared for growth, regulatory progress with the FDA, an evolving product pipeline, and a commercial organization reshaped for scale. Our focus now is to turn these building blocks into evidence-based outcomes for healthcare providers and individuals, as well as to shareholder value. Jakob Knudsen CEO
Page 6
6 The performance of H1 2026 reflects a marked increase in revenue, driven by our U.S. partner taking delivery of their minimum order – actual roll-out to end users in the U.S. remains the key milestone ahead 1,869 5,101 +173% -5,871 -3,944 -33% H1, 2025 H1, 2026 11,878 17,635 Financial results in H1, 2026 (H1, 2025 results in brackets) • Revenue increased by 173% to TDKK 5,101 (TDKK 1,869) • Operating expenses amounted to TDKK -8,253 (TDKK -9,485) • Operating loss decreased by 33% to TDKK -3,944 ( TDKK -5,871) • Net loss decreased by 47% to TDKK -3,199 (TDKK -6,031) • Cash and cash equivalents at the end of the period amounted to 17,635 (TDKK 11,878) Revenue Operating loss Cash balance TDKK Josephine Baum Jørgensen “The first half of 2026 showed a significant increase in revenue compared with the same period last year, which is very encouraging. As a result, we recently communicated revised guidance for the year. It is, however, important to be clear about what sits behind the development: the increase largely reflects suPARbio , our U.S. partner, taking delivery of the minimum order under our 2024 distribution agreement – in effect, building up stock rather than yet reflecting testing at scale. This also drove both operating loss and net loss down year-over-year. We remain closely engaged with suPARbio and continue to support them operationally as they build out capacity.” Josephine Baum Jørgensen, CFO
Page 7
7 In H1 2026, ViroGates advanced its collaboration with Sobi and made an FDA submission, developed suPARnostic® POC+ further, and took important steps in the U.S. commercial partnership Business highlights in H1 2026 • ViroGates and Sobi finalized the clinical and analytical development work underpinning suPARnostic® TurbiLatex for commercial use in the U.S. in combination with the pharmaceutical product Kineret® (anakinra), and compiled the full application for a De Novo filing with the U.S. FDA – submitted in April 2026, as announced in Company Announcement No. 3-2026 of 8 April 2026. • ViroGates and GENSPEED Biotech advanced suPARnostic® POC+ from proof of concept into further testing and validation during the period. This is needed before an IVDR application in the EU can be compiled. • ViroGates’ U.S. partner, suPARbio , took delivery of the minimum order under the 2024 distribution agreement, building up stock ahead of scalable commercial launch. A tangible step in the U.S. roll-out, which ViroGates continues to support closely. • By the end of H1 2026, ViroGates reports a recurring customer base of 20 customers (19 at the end of H1 2025).
Page 8
8 The full-year financial guidance for 2026 is maintained at 6.5 to 8 DKKm in revenue and -10 to -12 DKKm in EBIT Full-year outlook, 2026 • The strategic refocusing that ViroGates is undergoing continues to progress; however, such a transition inherently involves a degree of uncertainty. An evaluation of sales data from H1 2026 shows that longevity-related customers now account for a substantial share of revenue. This marks a meaningful step up from prior periods, but currently also reflects a single large distribution account rather than broad-based, recurring demand across the segment. ViroGates continues working to build a more scalable longevity customer base by targeting laboratories, clinic chains, and new partners specializing in preventive health services. • In parallel, ViroGates continues to work closely withsuPARbio , serving the U.S. longevity market. The recently revised guidance reflects the significant potential of the partnership, while accounting for the fact that the actual roll-out and testing volumes in the U.S. market are yet to materialize. The U.S. longevity, prevention, and population-wide health screening continues to be a key market for suPARnostic®. • ViroGates continues its collaboration with Sobi to obtain marketing clearance for suPARnostic® TurbiLatex in the US. The De Novo application, submitted in April 2026 (cf. Company Announcement No. 3-2026), remains under review. This work is not expected to have a revenue impact within the remainder of the year. • Following the changes to ViroGates' commercial organization announced on 3 August 2026 (cf. Company Announcement No. 6-2026), guidance accounts for the implementation of the new structure and personnel during H2 2026. • The recently revised financial guidance for 2026, as communicated in Company Announcement No. 7-2026, is maintained. ViroGates closely monitors financial performance and will update its guidance accordingly. 6.5 to 8 DKKm revenue in 2026 -10 to -12 DKKm EBIT in 2026 Full-year guidance, 2026
Page 9
9 Contents Summary Management review Financial statements Statement by the Board and Executive Management 4 9 14 23
Page 10
10 In H1 2026, ViroGates deepened its commercial alliances and laid the groundwork for a go-to-market model built on scale A shift toward scalable, partnership-led growth Jakob Knudsen As demand for preventive health and longevity grows, ViroGates is evolving its go-to-market strategy. We are focusing on a commercial model to pursue more scalable partnerships with established players who have direct market access. Collaboration with Sobi We have continued our close collaboration with Sobi on the regulatory process for U.S. market clearance of suPARnostic® TurbiLatex. As previously communicated, the pathway for U.S. entry is through a De Novo application, as the product is considered a novel, low-to-moderate risk medical device without a suitable predicate for a 510(k) clearance. The application includes analytical validation data, clinical data from the SAVE-MORE phase 3 trial, and additional supporting clinical evidence obtained specifically for this project and was submitted to the FDA in April 2026 (cf. Company Announcement No. 3-2026). The revised suPARnostic® POC+ has been optimized specifically for the preventive health and longevity market, with improved precision in the lower suPAR range relevant to this population. The remaining milestone is to complete analytical and minor clinical validation. The POC+ format is a natural fit for our scalability ambition: unlike testing that requires an IV blood draw, a fingerprick product can be offered far beyond the current clinical setting, e.g., at pharmacies, wellness and longevity clinics, meaningfully widening the population that can access suPAR testing as part of everyday health monitoring. Optimizing POC+ for longevity suPARbio , our U.S. commercial partner, is a great example of this approach: a partnership designed to reach the U.S. longevity and health- management market, rather than one clinic relationship at a time. The dynamic above is also one of the main reasons we have restructured internally. The role of the newly created Vice President of Business Development position is to help build such partnerships and market access with healthcare providers and commercial players across key markets, and to refine and accelerate this new go-to-market strategy (cf. Company Announcement No. 6-2026 of 3 August 2026). We see this as the natural next step in the same direction we have been moving throughout H1 2026: fewer, larger relationships that can scale faster than a traditional sales model.
Page 11
11 Financial highlights Note: N/A = not meaningful. Percentage changes are not presented where the comparison-period base value is too small to provide a meaningful denominator, as the resulting percentage would not reflect meaningful information about underlying performance. Key figures and ratios DKK (‘000) unless otherwise stated H1, 2026 H1, 2025 % change 2025 INCOME STATEMENT Net revenue 5,101 1,869 173% 5,307 Other income 224 2,999 -93% 3,597 Gross profit/loss 4,309 3,615 19% 6,621 Operating profit/loss -3,944 -5,871 -33% -10,472 Financial income and expenses, net 199 -514 -139% -757 Profit/loss for the period before tax -3,745 -6,385 -41% -11,229 Profit/loss for the period -3,199 -6,031 -47% -10,397 BALANCE SHEET Assets 22,077 17,985 23% 30,589 Equity 16,204 4,765 240% 19,403 Liabilities 5,873 8,976 -35% 3,475 CASH FLOW STATEMENT Cash flows from operating activities -8,090 -76 N/A -4,125 Cash flows from investment activities 0 0 - 5 Cash flows from financing activities -572 -255 125% 18,209 Investment in tangible fixed assets 0 0 - 0 Total cash flows -8,662 -331 N/A 14,089 DKK unless otherwise stated H1, 2026 H1, 2025 % change 2025 Rate of return (%) -110,43 -121,75 -9% -290,60 Share price, end of period 10.90 7.80 40% 13.45 Equity ratio (%) 73% 26% 177% 63% Employees, end of period (#) 7 7 - 7
Page 12
12 Financial highlights (continued) Revenue by product DKKm, % of total 60% 83% 13% 24% 14% 3% H1, 2025 2% H1, 2026 1.9 5.1 2% TurbiLatex Quick Triage ELISA Other Revenue by geographic area DKKm, % of total 24% 68% 74% 31% 2% H1, 2025 1% H1, 2026 1.9 5.1 Europe North America ROW Note: Regional split uses the United Nations geoscheme created by the UNSD.
Page 13
13 Thomas Krarup Financial highlights (continued) Recurring customers by segment (# by end of period) Note: A recurring customer is defined as a customer that has placed at least two orders within the trailing 12 months, with a combined order value exceeding EUR 10,000. Clinical routine customers are those using suPARnostic® products in routine patient or client handling and processes (e.g. clinics, laboratories, or hospitals), while research customers are those using suPARnostic® products for research purposes (e.g. CROs, university hospitals, or organizations using suPARnostic® in trials and studies). 9 9 10 11 H1, 2025 H1, 2026 19 20 Clinical routine Research "In the first half of 2026, our routine business kept moving toward longevity and preventive care, as chronic inflammation gains ground as a key marker of long-term health risk. We are focused on deepening ties with central labs, clinic networks, and specialized partners who are embedding suPAR into routine workflows rather than using it as a one-off. As I prepare to step down from my role at the end of September, I'll be following ViroGates' continued progress closely – it's an exciting road ahead, and I'm confident the team will keep building on this momentum." Thomas Krarup, VP of Global Sales & Marketing
Page 14
14 Contents Summary Management review Financial statements Statement by the Board and Executive Management 4 9 14 23
Page 15
15 Income Statement PROFIT & LOSS Amounts in DKK (‘000) Note Q2, 2026 Q2, 2025 % change H1, 2026 H1, 2025 % change 2025 Net revenue 3,798 667 469% 5,101 1,869 173% 5,307 Other income 224 2,999 -93% 224 2,999 -93% 3,597 Cost of goods/services sold -688 -584 18% -1,015 -1,254 -19% -2,283 Gross profit 3,334 3,082 8% 4,309 3,615 19% 6,621 Sales and distribution costs 1 -1,473 -1,539 -4% -2,874 -2,958 -3% -5,365 Research and development costs -2,025 -3,703 -45% -3,784 -4,755 -20% -8,143 Administrative costs -908 -959 -5% -1,595 -1,772 -10% -3,585 Operating loss -1,073 -3,118 -66% -3,944 -5,871 -33% -10,472 Financial income 411 32 N/A 419 41 N/A 47 Financial expenses -109 -294 -63% -221 -555 -60% -803 Loss before tax -770 -3,380 -77% -3,745 -6,385 -41% -11,229 Tax on profit/loss for the period 2 183 133 37% 546 354 54% 832 Loss for the period -588 -3,247 -82% -3,199 -6,031 -47% -10,397 Proposed distribution of loss Retained profit -588 -3,247 -82% -3,199 -6,031 -47% -10,397 Total -588 -3,247 -82% -3,199 -6,031 -47% -10,397
Page 16
16 Balance Sheet ASSETS Amounts in DKK (‘000) Note Q2, 2026 Q2, 2025 % change 2025 Rent deposit and other receivables 186 181 3% 186 Fixed asset investments 3 186 181 3% 186 Finished goods and goods for resale 1,451 2,373 -39% 1,754 Inventories 1,451 2,373 -39% 1,754 Trade receivables 409 1,646 -75% 1,166 Other receivables 346 259 33% 227 Corporation tax receivable 1,378 1,189 16% 832 Prepayments and accrued income 673 459 46% 128 Receivables 2,805 3,553 -21% 2,353 Cash and cash equivalents 17,635 11,878 48% 26,297 Current assets 21,891 17,804 23% 30,403 Assets 22,077 17,985 23% 30,589 EQUITY AND LIABILITIES Amounts in DKK (‘000) Note Q2, 2026 Q2, 2025 % change 2025 Share capital 9,284 7,737 20% 9,284 Retained profit 6,920 -2,972 -333% 10,119 Equity 4 16,204 4,765 240% 19,403 EIFO loan 2,700 3,931 -31% 3,330 Non-current liabilities 2,700 3,931 -31% 3,330 EIFO loan 1,233 1,114 11% 1,293 Trade payables 948 1,704 -44% 632 Other liabilities 992 6,471 -85% 5,931 Current liabilities 3,173 9,289 -66% 7,856 Liabilities 5,873 13,220 -56% 11,186 Equity and liabilities 22,077 17,985 23% 30,589 Contingencies 5
Page 17
17 Cash Flow Statement CASH FLOW Amounts in DKK (‘000) Note Q2, 2026 Q2, 2025 % change H1, 2026 H1, 2025 % change 2025 Profit/loss for the period -588 -3,247 -82% -3,199 -6,031 -47% -10,397 Reversed tax on profit/loss for the period 183 -133 -237% 546 -354 -254% 3 Corporation tax received 0 0 - 0 0 - 835 Change in inventory 127 -200 -163% 303 438 -31% 1,057 Change in receivables -78 1,784 -104% -453 182 -348% 544 Change in current liabilities (ex bank and tax) -3,998 2,702 -248% -5,287 5,688 -193% 3,833 Cash flows from operating activity -4,354 907 -580% -8,090 -76 N/A -4,125 Purchase of tangible fixed assets 0 0 - 0 0 - 0 Purchase of financial assets 0 0 - 0 0 - 5 Cash flows from investing activity 0 0 - 0 0 - 5 Subscription of share capital 0 0 - 0 0 - 19,005 Loan -291 -255 14% -572 -255 125% -795 Cash flows from financing activity -291 -255 14% -572 -255 125% 18,209 Change in cash and cash equivalents -4,645 652 N/A -8,662 -330 N/A 14,089 Cash and cash equivalents at 1 April/1 January 22,280 11,226 98% 26,297 12,208 115% 12,208 Cash and cash equivalents at end of period 17,635 11,878 48% 17,635 11,878 48% 26,297 Specification of cash and cash equivalents at end of period: Cash and cash equivalents 17,635 11,878 48% 17,635 11,878 48% 26,297 Cash and cash equivalents 17,635 11,878 48% 17,635 11,878 48% 26,297
Page 18
18 Notes to the financial statements Amounts in DKK (‘000) unless otherwise stated Q2, 2026 Q2, 2025 % change 2025 Average number of employees (#) 7 7 0% 7 Sales & Marketing 1,066 1,043 2% 3,761 Research & Development 704 681 3% 2,456 Administration 363 404 -10% 1,458 Total staff costs 2,132 2,128 0% 7,676 1 Staff costs The remuneration for the Board of Directors and Executive Management are published annually in the Company’s Remuneration Report in connection with the Annual Report. Amounts in DKK (‘000) Q2, 2026 Q2, 2025 % change 2025 Calculated tax on taxable income 183 133 37% 832 Total 183 133 37% 832 2 Tax on profit/loss for the period Amounts in DKK (‘000) Q2, 2026 Q2, 2025 % change 2025 Rent deposit and other receivables Cost at 1 April 2026 / 2025 186 181 3% 181 Additions 0 0 - 5 Cost at Q2 2026, Q2 2025, 2025 186 181 3% 186 Carrying amount of Q2 2026, Q2 2025, 2025 186 181 3% 186 3 Fixed asset investments
Page 19
19 Notes to the financial statements (continued) 5 Contingencies Amounts in DKK Q2, 2026 Q2, 2025 % change 2025 Share capital 9,284,476 7,737,064 20% 7,737,064 Retained profit 10,118,599 3,058,415 231% 3,058,415 Equity at 1 April 19,403,075 10,795,479 80% 10,795,479 Capital increase (share capital) 0 0 - 1,547,412 Capital increase (retained profit) 0 0 - 17,717,867 Cost regarding capital increase 0 0 - -260,741 Proposed distribution of loss to retained profit -3,199,095 -6,030,848 -47% -10,396,943 Equity end of period 16,203,979 4,764,631 240% 19,403,075 4 Equity The Company's share capital consists of 9,284,476 shares of nom. 1 kr. The Company has 2.585 treasury shares of nom. 1 kr. which equals 0.03% of the total share capital. Under a resolution passed by the General Meeting, the Company may acquire treasury shares up to 10% of the share capital. The Company has provided a guarantee in the form of a bank deposit of DKK (‘000) 50 as security for all balances with Danske Bank. 6 Other external expenses Amounts in % of total expenses Q2, 2026 Q2, 2025 % change 2025 Sales expenses (incl. staff) in % of total expenses 33.4% 24.8% 35% 31.4% R&D expenses (incl. staff) in % of total expenses 46.0% 59.7% -23% 47.6%
Page 20
20 Active management & board warrant programs (as of 31 March 2026) Note: Numbers may not add up due to rounding. Mark Da Silva (resigned CFO) still has 11,242 outstanding warrants in the 2019 warrant program. A group of employees no longer employed by ViroGates still has 3,625 outstanding warrants in total in the 2022 program. The 2015 warrant program is not listed above, as all non-exercised warrants in the program have expired. 2019 warrant program Warrants (#, % of total) Warrants allocated Warrants exercised Warrants expired Warrants outstanding (vested) Warrants outstanding (total) Jakob Knudsen (CEO) 56,439 (100%) 13,253 (23%) 16,931 (30%) 26,255 (47%) 26,255 (47%) Thomas Krarup (VP S&M) 20,209 (100%) 10,102 (50%) 1,012 (5%) 9,095 (45%) 9,095 (45%) Jesper Eugen-Olsen (CSO) 8,084 (100%) 5,051 (62%) 0 (0%) 3,033 (38%) 3,033 (38%) 2019 program details • Strike price at 35 DKK • 12% annual price increase from vesting date • Expiry five years from vesting date 2022 warrant program Warrants (#, % of total) Warrants allocated Warrants exercised Warrants expired Warrants outstanding (vested) Warrants outstanding (total) Other employees 12,500 (100%) 0 (0%) 0 (0%) 12,500 (100%) 12,500 (100%) Patrik Dahlen (Chairman) 31,700 (100%) 0 (0%) 0 (0%) 29,322 (92%) 31,700 (100%) Válerie Soulier (BM) 9,510 (100%) 0 (0%) 0 (0%) 8,797 (93%) 9,510 (100%) Josephine Baum (CFO) 30,000 (100%) 0 (0%) 0 (0%) 23,250(78%) 30,000 (100%) 2022 program details • Strike price at 129 DKK (other employees), 57.8 DKK (BoD), and 49.50 DKK (CFO) • 12% annual price increase from vesting date • Expiry five years from vesting date Warrants (#, % of total) Warrants allocated Warrants exercised Warrants expired Warrants outstanding (vested) Warrants outstanding (total) Jakob Knudsen (CEO) 55,000 (100%) 0 (0%) 0 (0%) 17,187 (31%) 55,000 (100%) Jesper Eugen-Olsen (CSO) 30,000 (100%) 0 (0%) 0 (0%) 9,375 (31%) 30,000 (100%) Thomas Krarup (VP S&M) 25,000 (100%) 0 (0%) 0 (0%) 7,812 (31%) 25,000 (100%) Josephine Baum (CFO) 15,000 (100%) 0 (0%) 0 (0%) 4,687 (31%) 15,000 (100%) Other employees 5,000 (100%) 0 (0%) 0 (0%) 1,563 (31%) 5,000 (100%) 2025 warrant program 2025 program details • Strike price at 13 DKK • 12% annual price increase from vesting date • Expiry five years from vesting date
Page 21
21 Shareholdings of the board and management Note: 1) Executive management registered with the Danish Business Authority; 2) Person Discharging Managerial Responsibilities (permanent insider with access to all information). Management (role) Executive Management1 Management PDMR2 Shares (#, end of Q2, 2026) Shares (#, end of Q1, 2026) Shares (#, end of last year) Jakob Knudsen (CEO) Yes Yes Yes 118,914 118,914 118,914 Josephine Baum Jørgensen (CFO) No Yes Yes 1,200 1,200 1,200 Thomas Krarup (VP Sales & Marketing) No Yes Yes 16,116 16,116 16,116 Jesper Eugen-Olsen (CSO) No Yes No 304,205 301,558 301,558 Board (role) PDMR2 Shares (#, end of Q1, 2026) Shares (#, end of Q4, 2025) Shares (#, end of last year) Patrik Dahlén (Chairman) Yes 10,570 10,570 10,570 Lars Kongsbak (Board member) Yes 6,968 6,968 6,968 Valérie Soulier (Board member) Yes 0 0 0
Page 22
22 Trading windows for persons discharging managerial responsibilities Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Trading windows for PDMRs • Closed periods: In accordance with MAR, ViroGates has a closed period of 30 days before the announcement of an interim financial report or a year-end report • Open periods: ViroGates has an open period of six weeks after the announcement of an interim financial report or a year-end report (if an open period of a previous report overlaps a closed period of an upcoming report, the closed period applies) Q1 report 7 May Annual report 2025 26 Mar Open trading window 26 Mar - 7 Apr 2026 Open trading window 7 May - 10 Jun H1 (Q2) report 20 Aug Q1-Q3 report 5 Nov Open trading window 20 Aug – 6 Oct Open trading window 5 Nov - 17 Dec Note: PDMRs can only trade shares during open trading windows given no insider information at the time of trading.
Page 23
23 Contents Summary Management review Financial statements Statement by the Board and Executive Management 4 9 14 23
Page 24
24 Statement by the Board of Directors and Executive Management Today, the Board of Directors and the Executive Management have discussed and approved the Annual Report of ViroGates A/S for the first half year of 2026 (1 January – 30 June 2026). The interim report has been created in accordance with IAS 34, Interim Financial Reporting as approved by the EU and additional disclosure requirements for companies listed on NASDAQ First North Denmark. In our opinion, the financial statements give a true and fair view of the company’s financial position on 30 June 2026 and of the results of the company’s operations and cash flows for the financial period 1 January – 30 June 2026. The management’s review includes, in our opinion, a fair presentation of the matters dealt with in the report. The interim report is unaudited. Birkerød, 20 August 2026 Statement Executive Management Board of Directors Jakob Ole Knudsen CEO Lars Kongsbak Patrik Dahlen (Chairman) Valérie Soulier